Showing results (81-90 of 88) with videos related to
Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cellsSimon P Newman, Paul A Foster, Chloe Stengel, et al.Molecular and Cellular Endocrinology|September 9, 2008
The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitorsNigel Vicker, Christopher M Sharland, Wesley B Heaton, et al.Journal of Medicinal Chemistry|February 17, 2006
Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1Gillian M Allan, Harshani R Lawrence, Josephine Cornet, et al.Molecular Cancer Therapeutics|August 30, 2008
Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallographyL W Lawrence Woo, Delphine S Fischer, Christopher M Sharland, et al.International Journal of Cancer|January 10, 2008
17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancerJoanna M Day, Paul A Foster, Helena J Tutill, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitorSusannah J Stanway, Atul Purohit, L W Lawrence Woo, et al.Chemical Communications (Cambridge, England)|April 14, 2010
Chimeric microtubule disruptorsMathew P Leese, Fabrice Jourdan, Meriel R Kimberley, et al.Journal of Medicinal Chemistry|February 12, 2008
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agentsMathew P Leese, Fabrice L Jourdan, Keira Gaukroger, et al.Pageof 9